abstract |
The invention provides a method of enhancing bone fracture healing involving administering a sclerostin inhibitor. In one aspect, the invention includes use of a therapeutically effective amount of sclerostin binding agent to treat a bone fracture, wherein one or more administrations of the sclerostin binding agent are administered over a treatment period lasting at least two weeks and beginning within two weeks of the fracture. |